Oncology Development
Pfizer Medical Info
Recent Scientific Presentations
All Pfizer Enrolling Trials
Become a Trial Investigator

Breadcrumb

Home

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

a0FVy000004iHVtMAM - ACCP 2025 KAT6i Dose Opt Poster (edit from copy)

Geo Regions

Please verify that you are
a Healthcare Professional

This information is intended for Healthcare Professionals

I am a Healthcare/Medical Professional

I am NOT a Healthcare/Medical Professional

This website is intended for use by Healthcare/Medical Professionals

You will now be re-directed to www.pfizermedicalinformation.com

Please select your location

Africa/Middle East

Asia Pacific

Canada

China

Europe

Japan

Latin America

United States

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.

Please acknowledge that you understand this before proceeding.

Back

Molecule overview Clinical trials Scientific presentations

Model-Informed Recommended Phase 3 Dose for a novel KAT6 inhibitor, PF-07248144, Following Dose Optimization in 2L+ ER+/HER2- Metastatic Breast Cancer (mBC) population

/sites/default/files/scientific_presentation/ACCP_2025_KAT6i_Dose.pdf

Download File

For HCP informational purposes only. Content is not intended to be shared with potential study participants. Patients may access Pfizerclinicaltrials.com.

Terms of Use
Privacy
Sitemap

This site is intended for US HCPs and HCPs in countries where accessing this site is permitted